OpenEvidence Doubles Its Valuation to $12 Billion with New Funding

OpenEvidence, a medical artificial intelligence startup, has doubled its valuation to $12 billion thanks to a new funding round.

OpenEvidence Doubles Its Valuation to $12 Billion with New Funding
Logo of OpenEvidence, a medical artificial intelligence startup

OpenEvidence, a medical artificial intelligence startup, has recently completed a $250 million Series D funding round, bringing its valuation to $12 billion. This is double the $6 billion valuation it obtained just three months earlier. The round was co-led by Thrive Capital and DST Global, bringing the total funding raised by the company to nearly $700 million over the past 12 months.

A Rapid Rise in Medical AI

Founded in 2022 by Daniel Nadler and Zachary Ziegler, OpenEvidence has developed an artificial intelligence platform designed to assist doctors in clinical decisions. The platform is trained exclusively on data from scientific journals and medical guidelines, ensuring high-quality, reliable information. This approach sets OpenEvidence apart from other AI tools that use data from the open internet, reducing the risk of incorrect or misleading information.

Impact and Adoption by Healthcare Professionals

According to the company, the platform is used by more than 40% of doctors in the United States, with significant growth in the number of clinical consultations supported. In December 2025, OpenEvidence assisted around 18 million clinical consultations, a significant increase over the previous year. This indicates growing trust in, and reliance on, AI tools among healthcare professionals to improve the quality of care provided to patients.

Competition in Healthcare AI

Despite OpenEvidence's success, the healthcare AI sector is seeing new players enter. Recently, OpenAI introduced "ChatGPT Health" and Anthropic launched "Claude Healthcare", both AI tools designed for the healthcare field. However, OpenEvidence stands out for its specific focus on doctors' needs and for its use of verified medical data, offering a competitive advantage in the reliability and accuracy of the information it provides.

Future Outlook and Investments

The recent funding round and the increase in valuation reflect investors' growing interest in AI applied to medicine. With the backing of prominent investors such as Thrive Capital, DST Global and Sequoia, OpenEvidence is well positioned to expand its platform further, invest in research and development and grow its user base worldwide. The company said the funds raised will be used to further improve the platform's capabilities and to support adoption by a growing number of healthcare professionals.

Takeaway

  • Doubled Valuation: OpenEvidence saw its valuation rise from $6 billion to $12 billion in just three months, highlighting growing interest in the medical AI sector.
  • Widespread Adoption: The platform is used by more than 40% of doctors in the United States, with a significant increase in the clinical consultations supported.
  • Emerging Competition: New players such as OpenAI and Anthropic are entering the market, but OpenEvidence stands out for its use of verified medical data and its specific focus on doctors' needs.
  • Growth Outlook: With the backing of prominent investors, OpenEvidence is well positioned to expand its platform and invest in research and development.

OpenEvidence's rapid rise underscores the growing importance of artificial intelligence in healthcare and the potential of such technologies to improve the quality of care and the efficiency of healthcare professionals.